Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, Carcinoembryonic Antigen, and Alpha-Fetoprotein on the Dimension Vista® System

Clinical Biochemistry

Volumn 44, Issue 13, 2011, Pages 1128-1136

  Christenson, Robert H ^a   Cervelli, Denise R ^b   Sterner, Jamie ^b   Bachmann, Lauren M ^d   Rebuck, Heather ^a   Gray, Jeffery ^a   Kelley, Walter E ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Siemens Healthcare Diagnostics   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

AFP; Assays; CA 125 II; CA 15 3; CA 19 9; CEA; Dimension Vista System

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ANALYTICAL ERROR; ANALYZER; ARTICLE; BLOOD SAMPLING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SERUM;

ALPHA-FETOPROTEINS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMANS; LIMIT OF DETECTION; MUCIN-1; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 80051686344     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.06.009     Document Type: Article

References (19)

1. Sturgeon C.M., Duffy M.J., Stenman U.-H., et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008, 54(12):e11-e79.
2. Anon. Practice guidelines and recommendations for use of tumor markers in the clinic.
3. Yarbro J.W., Page D.L., Fielding L.P., Partridge E.E., Murphy G.P. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999, 86(11):2436-2446.
4. Yarbro J.W., Page D.L., Fielding L.P., Partridge E.E., Murphy G.P. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999, 86(11):2436-2446.
5. Anon NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995, 273(6):491-497.
6. Menon U., Jacobs I.J. Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 2000, 12(1):39-42.
7. Locker G.Y., Hamilton S., Harris J., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24(33):5313-5327.
8. Thomas G., Jones W., VanOosterom A., Kawai T. Consensus statement on the investigation and management of testicular seminoma 1989. Prog Clin Biol Res 1990, 357:285-294.
9. Vastag B. Testicular cancer seen as "stalking horse" for other cancers. J Natl Cancer Inst 1999, 91(21):1801-1802.
10. Kerbrat P., Lhommé C., Fervers B., et al. Ovarian cancer. Br J Cancer 2001, 84(Suppl 2):18-23.
11. Duffy M.J. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998, 35(Pt 3):364-370.
12. Smith R.A., Cokkinides V., von Eschenbach A.C., et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002, 52(1):8-22.
13. Ullman E.F., Kirakossian H., Singh S., et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci USA 1994, 91(12):5426-5430.
14. Erden G., Barazi A.O., Tezcan G., Yildirimkaya M.M. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals. Scand J Clin Lab Invest 2008, 68(3):212-218.
15. Anon. Desirable Specifications for Total Error, Imprecision, and Bias, derived from intra- and inter-individual biologic variation. Available at: http://www.westgard.com/biodatabase1.htm.
16. Ricós C., Alvarez V., Cava F., et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999, 59(7):491-500.
17. Trapé J., Botargues J.M., Porta F., et al. Reference change value for alpha-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. Clin Chem 2003, 49(7):1209-1211.
18. Burtis C., Ashwood E. Tietz textbook of clinical chemistry 1999, W.B. Saunders Company, Philadelphia, PA. 3rd ed.
19. Sturgeon C, Diamandis EP. Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Available at: Accessed May 12, 2011. http://www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/major/Documents/TumorMarkersMajor10.pdf#page=1.